Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our Privacy policy.

Skip to content

Marketed Products

Our reward is real progress. The satisfaction of knowing that what we are doing really helps

Our reward is real progress. The satisfaction of knowing that what we are doing really helps. We have a marketed range of drug-free treatments for osteoarthritis that reduces pain and stiffness, and improves joint movement and offers welcome relief from a condition that effects 20% of adults worldwide.


Our products

Flexiseq is a topical drug-free gel for lubricating the cartilage in joints to relieve pain and stiffness, and improve joint function associated with all stages of osteoarthritis.

Flexiseq Osteoarthritis: Our maximum strength formulation

Flexiseq Osteoarthritis: Our maximum strength formulation

If you have diagnosed osteoarthritis, nothing but the best will do. That’s why Flexiseq Osteoarthritis is loaded with our max strength formulation, tested in clinical trials with the most demanding patients. Flexiseq Osteoarthritis is clinically proven*, drug free relief from the pain and stiffness of osteoarthritis. A drug-free, sustainable solution to effectively relieve the pain and stiffness of osteoarthritic joints to keep you moving.

Flexiseq Active: Our lighter strength formulation

Flexiseq Active: Our lighter strength formulation

Flexiseq Active contains a lighter formulation of our original, drug free, joint lubricating technology, for active joints affected by everyday wear and tear. Whether you are cycling to work, walking the hills, jogging with the dog or taking a weekend Zumba class, Flexiseq Active provides trusted relief from the pain and stiffness of joint wear and tear to keep you moving.

Len Goodman, Ascension’s Flexiseq Ambassador

Talking about the LetsGetMoving campaign Len said, “Flexiseq genuinely helped me with my arthritis, which is why I was delighted to be asked to be their Ambassador. Together we’re on a mission to get people moving".

About Flexiseq

Research on joint disorders
Patients with joint disorders such as OA have been found to have reduced levels of synovial lubricants that play a key role in protecting articulating cartilage. It has been suggested that where mechanical abnormalities have triggered the body’s repair process, which manifest themselves in pain and inflammation. Research has shown that liposomal aggregates that are highly compressible, soft and are highly hydrated make for efficient biolubricants. A study with topically applied, fluorescently labelled Sequessome vesicles showed that not only did the vesicles travel to the synovium, they were intact and located preferentially on the surface of the cartilage, forming a protective, lubricating layer.

Flexiseq efficacy
Exploiting this lubricating mechanism, Flexiseq demonstrated clear efficacy in large scale Phase III 12 week trial, comparable to the oral selective, COX2 painkiller, celecoxib. These data are shown below:

WOMAC pain sub scale:
mean difference from baseline

Proportion of patients reporting
Gastrointestinal Events

Flexiseq safety profile
The excellent safety profile has been further demonstrated by the total lack of any systemic side effects being related to the product in over 90 million doses sold worldwide.

What healthcare professionals are saying about FlexiSeq
The advantages of Flexiseq have been recognised by key persons within the arthritis medical community and leading physio-therapy/sports rehabilitation:

“There are fewer and fewer safe, available, pain-relieving options for people with osteoarthritis. If this product can relieve their long-term pain without side-effects, then that’s good news for the millions of people who suffer with this debilitating condition.” Arthritis Research UK

“This is a fantastic product and one the medical team are proud and happy to have associated with the Club” – Joe Collins, former Head of Saracens Medical Team and now Head of Buffalo Sabres (ice hockey)

Medical Team Flexiseq trial data have been published in a number of journals: CURRENT Medical research and Opinion, Rheumatology, Journal of Rheumatology, and Journal of pain research.